Latest Content

Investigator Elizabeth Lee, MD, discusses efficacy and safety data for rinatabart sesutecan in patients with endometrial cancer.

A look at the current state of cancer, from survival rates to federal research budgets.

Kelly Grosklags, LICSW, BCD, FAAGC, FT, shares advice for dealing with grief in oncology nursing, from treating patients in denial to showing emotion in front of them.

Dato-DXd has been given priority review for the treatment of patients with unresectable/metastatic triple-negative breast cancer.

Multicancer early detection tests may expand screening options, but does the benefit outweigh the uncertainties?

In a world of unfamiliarity and uncertainty, patient advocates help guide those with cancer through challenging diagnoses and the decisions that come with them.

Nurses are called to honor Alex Pretti’s memory through compassion and action.

The FDA approved a larger vial size of nelarabine for the treatment of pediatric and adult patients with T-ALL and T-LBL.

Updates in ovarian cancer include multiple fast track designations and breakthrough therapy status for new drugs in the clinical space.

Plus, a phase 1 breast cancer vaccine, updated NCCN guidelines, and a combination with standard-of-care potential in triple-negative breast cancer.

The frontline combination of nivolumab and ipilimumab demonstrated long-term safety and efficacy in patients with unresectable hepatocellular carcinoma.

Kelly Grosklags, LICSW, BCD, FAAGC, FT, shares insights for dealing with grief as an oncology clinician.

Chemoradiotherapy led to OS and RFS benefit in high-risk patients with chemoradiotherapy vs radiotherapy alone.